Back to Search Start Over

Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancer.

Authors :
Pagan, Eleonora
Ruggeri, Monica
Bianco, Nadia
Bucci, Eraldo Oreste
Graffeo, Rossella
Borner, Markus
Giordano, Monica
Gianni, Lorenzo
Rabaglio, Manuela
Freschi, Andrea
Cretella, Elisabetta
Seles, Elena
Farolfi, Alberto
Simoncini, Edda
Ciccarese, Mariangela
Rauch, Daniel
Favaretto, Adolfo
Honecker, Friedemann
Berardi, Rossana
Franzetti-Pellanda, Alessandra
Source :
Breast; Oct2024, Vol. 77, pN.PAG-N.PAG, 1p
Publication Year :
2024

Abstract

Although younger age has been negatively associated with persistence to adjuvant endocrine therapy (ET), factors contributing to non-persistence remain poorly understood. We assessed factors associated with non-persistence to ET and described the 5-year trajectories of quality of life (QoL) and symptoms in young women (≤40 years) with hormone receptor-positive breast cancer (BC). We retrieved data on clinical characteristics and non-persistence from the medical annual records in the European cohort of the "Helping Ourselves, Helping Others: The Young Women's BC Study" (IBCSG 43-09 HOHO). Women completed surveys at baseline, biannually for three years, and annually for another seven years. Data collection included sociodemographic information, QoL aspects assessed by the Cancer Rehabilitation Evaluation System-Short Form and symptoms assessed by the Breast Cancer Prevention Trial symptom scales. Cox regression models were applied to identify factors associated with non-persistence. The cumulative risk of interrupting ET within 5 years was 27.7 % (95 % CI, 21.5–35.2). The QoL subscale scores remained stable over 5 years, with slight improvements in the physical subscale. Hot flashes decreased (p < 0.001), while vaginal problems intensified (p < 0.001) over time. Being married without children and having difficulties interacting and communicating with the medical team were significantly associated with non-persistence. Discussing the desire to conceive with partnered childless women and establishing a good relationship with the medical team may be important in addressing the non-persistence in young BC survivors. As recent data suggests the safety of pausing ET to conceive, this approach may be a reasonable future option to limit non-persistence. • Persistence to endocrine treatment in young women is poorly understood. • Quality of life remained stable over 5 years. • Hot flashes decreased and vaginal problems intensified over time. • Women being married without children were less likely to persist. • Good communicating with the medical team is important for persistence. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
09609776
Volume :
77
Database :
Supplemental Index
Journal :
Breast
Publication Type :
Academic Journal
Accession number :
179557180
Full Text :
https://doi.org/10.1016/j.breast.2024.103765